Novartis’ Pluvicto offers survival benefit in PSMA-positive mCRPC, says study
The Phase 3 trial has met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Dec 22
The Phase 3 trial has met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who…
28 Nov 22
The South Korean biotech firm claimed that the anticancer therapy candidate could complete chemotherapy with two doses in…
25 Nov 22
The two-dose vaccine, which leverages the same mRNA technology used in the Covid-19 vaccines developed by Pfizer and…
17 Nov 22
Zolbetuximab is an investigational monoclonal antibody that targets Claudin 18.2 and is used for the treatment of CLDN18.2-positive,…
15 Nov 22
The company will initiate a post-approval efficacy study in areas with active chikungunya virus (CHIKV) transmission, in collaboration…
01 Nov 22
The study evaluated the efficacy and safety of Reblozyl in treating anaemia due to very low-, low- or…
20 Oct 22
The FDA Emergency Use Authorisation decision was based on the findings of the phase 3 Prevent-19 clinical trial…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 Oct 22
The mid-stage trial is a randomised, double-blind study featuring 243 patients with metastatic non-squamous NSCLC who met certain…
28 Sep 22
The phase 3 confirmatory Clarity AD clinical trial of lecanemab also met all key secondary endpoints, while delivering…
23 Sep 22
The patient dosing with the haemophilia A gene therapy candidate is expected to start in October 2022 in…